Eviction from the Sanctuary: Development of Targeted Therapy Against Cell Adhesion Molecules in Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a malignant hematological disease afflicting hematopoiesis in the bone marrow. While 80-90% of patients diagnosed with ALL will achieve complete remission at some point during treatment, ALL is associated with high relapse rate, with the 5-year overall survival rate of 68%. The initial remission failure and the high rate of relapse can be attributed to intrinsic chemoprotective mechanisms that allow persistence of ALL cells despite therapy. These mechanisms are mediated, at least in part, through the engagement of cell adhesion molecules (CAMs) within the bone marrow microenvironment. ...
Source: Seminars in Oncology - July 10, 2017 Category: Cancer & Oncology Authors: Sonali P. Barwe, Anthony Quagliano, Anilkumar Gopalakrishnapillai Source Type: research
Current Challenges in the Management of Breast Cancer Brain Metastases
Approximately 50% of patients with advanced human epidermal growth factor 2 (HER2)-positive breast cancer and triple negative breast cancer (TNBC) ultimately develop breast cancer brain metastases (BCBM), which are associated with significant morbidity and mortality. The advent of HER2-directed therapy resulted in greatly improved survival outcomes, but unfortunately at the price of an increased cumulative incidence of BCBM. We review challenges in the management of BCBM, and potential treatment strategies, including novel agents such as poly-ADP ribose polymerase (PARP) inhibitors (olaparib, veliparib), cyclin dependent k...
Source: Seminars in Oncology - July 7, 2017 Category: Cancer & Oncology Authors: Ciara C. O ’Sullivan, Nicole N. Davarpanah, Jame Abraham, Susan E. Bates Source Type: research
Cancer therapies and the problem of me too many
I think its fair to say all large and many small pharmaceutical companies involved in developing cancer drugs are “into immunotherapy”. And nearly all are developing an anti-PD-1 or anti-PD-L1 molecule. The US Food and Drug Administration has already approved two of each. Many will claim they are different and we need to develop more. Such claims ring hollow. With yearly revenues of several billon dollars f or the foreseeable future why should we let Merck and Bristol Myers reap the harvest with pembrolizumab and nivolumab? Anyone who thinks a desire to share in the financial harvest is not the principal or exclusive r...
Source: Seminars in Oncology - July 6, 2017 Category: Cancer & Oncology Authors: Tito Fojo Source Type: research
Biomarker-driven and molecular targeted therapies for colorectal cancers
Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as poss...
Source: Seminars in Oncology - July 4, 2017 Category: Cancer & Oncology Authors: Marta Schirripa, Stacey A. Cohen, Francesca Battaglin, Heinz-Josef Lenz Source Type: research
Prevention of 5-fluorouracil –induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing
Life-threatening toxicities induced by widely-prescribed fluoropyrimidines remain a critical issue. Despite the accumulation for decades of evidence showing that dihydropyrimidine dehydrogenase (DPD) deficiency is a leading cause of 5-fluorouracil (5FU)-related toxicities [1 –3], there is still no consensus on the best strategy for identifying patients at risk. Upfront DPD screening has been recommended by the Clinical Pharmacogenetics Implementation Consortium [4], as well as by several national societies of biologists such as the Royal Dutch Pharmacists Association, the Italian Society of Pharmacology, and the French G...
Source: Seminars in Oncology - July 4, 2017 Category: Cancer & Oncology Authors: Marie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, Etienne Chatelut, Alexandre Evrard, Marie-Anne Loriot, Angelo Paci, Bernard Royer, Fabienne Thomas, Joseph Ciccolini Tags: Letter to the Editor Source Type: research
A molecular and preclinical comparison of the PD-1 –targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell death protein 1 (PD-1) –targeted antibodies nivolumab and pembrolizumab have been two of the lead molecules of this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion, but to a significant degree is a consequence of their molecular properties. Here we provide a molecular, precl inical, and early clinical comparison of the two antibodies, based on the available data and recent literature. (Source: Seminars in Oncology)
Source: Seminars in Oncology - July 4, 2017 Category: Cancer & Oncology Authors: Petros Fessas, Hassal Lee, Shinji Ikemizu, Tobias Janowitz Source Type: research
A Molecular and Preclinical Comparison of the PD-1 targeted T cell Checkpoint Inhibitors Nivolumab and Pembrolizumab
T cell checkpoint inhibition has a profound impact on cancer care and the two Programmed cell death protein 1 (PD-1) targeted antibodies nivolumab and pembrolizumab have been leading this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion, but to a significant degree is a consequence of their molecular properties. Here we provide a molecular, preclinical, and early clinical comparison of the two antibodies, based on the available data and recent literature. (Source: Seminars in Oncology)
Source: Seminars in Oncology - July 4, 2017 Category: Cancer & Oncology Authors: Petros Fessas, Hassal Lee, Shinji Ikemizu, Tobias Janowitz Source Type: research
Biomarker-Driven and Molecular Targeted Therapies for Colorectal Cancers
The improved clinical selection and the identification of new molecules and innovative strategies widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and will be probably soon adopted in the daily clinical practice. In the present review the role RAS, BRAF mutations, Her2 amplification, microsatellite instability and CpG Island Methylator Phenotype are reviewed and discussed according to their possible role as prognostic, predictive markers a...
Source: Seminars in Oncology - July 4, 2017 Category: Cancer & Oncology Authors: Marta Schirripa, Stacey A. Cohen, Francesca Battaglin, Heinz-Josef Lenz Source Type: research
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase (DPD) deficiency screening: The multiparametric approach is not convincing
To the Editor: (Source: Seminars in Oncology)
Source: Seminars in Oncology - July 4, 2017 Category: Cancer & Oncology Authors: Marie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, Etienne Chatelut, Alexandre Evrard, Marie-Anne Loriot, Angelo Paci, Bernard Royer, Fabienne Thomas, Joseph Ciccolini Source Type: research
outside front cover
(Source: Seminars in Oncology)
Source: Seminars in Oncology - June 1, 2017 Category: Cancer & Oncology Source Type: research
Masthead
(Source: Seminars in Oncology)
Source: Seminars in Oncology - June 1, 2017 Category: Cancer & Oncology Source Type: research
Editorial Board
(Source: Seminars in Oncology)
Source: Seminars in Oncology - June 1, 2017 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Seminars in Oncology)
Source: Seminars in Oncology - June 1, 2017 Category: Cancer & Oncology Source Type: research
outside front cover
(Source: Seminars in Oncology)
Source: Seminars in Oncology - April 1, 2017 Category: Cancer & Oncology Source Type: research
Masthead
(Source: Seminars in Oncology)
Source: Seminars in Oncology - April 1, 2017 Category: Cancer & Oncology Source Type: research
